Glenmark
Glenmark launches SUTIB (Sunitinib) - priced 96% lower than the innovator brand- Reduces the risk of kidney cancer progression by 58% ANI | Updated: Feb 16, 2021 12:24 IST
Mumbai (Maharashtra) [India], February 16 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India.
The drug is launched at a MRP that is approx. 96 per cent lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg) and Rs 1840 (12.5 mg) per month. Sunitinib is also approved by the US Food and Drug Administration (US FDA).
Kidney cancer (renal cell carcinoma) is a disease of uncontrolled cell growth in the lining of small tubes in the kidney. In the past decade, advances in research and drug development have begun to shift the paradigm of this disease.
Glenmark launches kidney cancer treatment drug in India priced 96% lower than innovator brand Greater Kashmir | Glenmark Pharma on Tuesday launched a generic kidney cancer treatment drug 'Sunitinib oral capsules' in India priced 96 per cent lower compared to the
Glenmark launches affordable drug to treat kidney cancer in India
Glenmark launches affordable drug to treat kidney cancer in India
16 February 2021 | News The drug is launched at a MRP that is approximately 96 per cent lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg) and Rs 1840 (12.5 mg) per month
Source credit: Shutterstock
Glenmark Pharmaceuticals has launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. The drug is launched at a MRP that is approximately 96 per cent lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg) and Rs 1840 (12.5 mg) per month. Sunitinib is also approved by the US Food and Drug Administration (US FDA).
New Delhi, Feb 16: Glenmark Pharma on Tuesday launched a generic kidney cancer treatment drug 'Sunitinib oral capsules' in India priced 96 per cent lower